Our Mission
PeopleBeatingCancer supports an evidence-based integrative approach to cancer care. For most newly diagnosed patients, FDA-approved therapies form the foundation of treatment, while evidence-based complementary therapies may help reduce side effects and improve survivorship.
Click the orange button to the right to learn more.
Category Archives for Pre-Myeloma
Treatment? Smoldering Multiple Myeloma
“Trials of lenalidomide (revlimid) in a less intensive approach has shown promise in delaying disease progression and should be investigated further in clinical trials.” You’ve been diagnosed
Continue readingMGUS- Slurring, Vision, Thick Blood?
Asymptomatic Monoclonal Gammopathy of Undermined Significance can cause symptoms. Hyperviscosity syndrome, the problems it causes and possible therapies… One of the most difficult aspects about an
Continue readingPre-Myeloma- SPB, MGUS, SMM
Pre-Myeloma- Single Bone Plasmacytoma, Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) Defined- Symptoms, Causes, Diagnostics- Pre-myeloma is a diagnostic
Continue readingChemo for Smoldering Multiple Myeloma???
“Nonhematologic grade 3 adverse events occurred in 21 smoldering multiple myeloma patients (38.9%) and included thromboembolism, rash, and lung infection, with no grade 4 events.” Yes, chemotherapy
Continue readingMGUS- Tingling?
Hi David- I was recently diagnosed with monoclonal gammopathy of undetermined significance (MGUS). It was found by labs done because of pins and needles in my arms and legs after a Covid vaccine. Several
Continue readingMGUS Dx- Cure vs. Control?
MGUS patients are more likely to develop more severe PN during treatment with certain drugs used to treat MM (e.g. bortezomib and thalidomide) Hi David- I was diagnosed with Monoclonal Gammopathy
Continue readingSmoldering Myeloma (SMM) – Chemo now, later?
“New studies (pre-habilitation) suggest that a multimodal approach that incorporates both physical and psychological prehabilitation interventions may be more effective than a unimodal approach that
Continue readingPre- Myeloma? Stage 1 Multiple Myeloma? Cure vs. Control
Should we treat patients with myeloma with multidrug, multitransplant combinations with the goal of potentially curing a subset of patients, recognizing that the risk of adverse events and effect on quality
Continue readingRisk of Progression for Smoldering Multiple Myeloma is Reduced…at what cost?
“Lenalidomide (Revlimid) induced a 72% reduction in the risk of progression to symptomatic disease in patients with smoldering multiple myeloma at 3 years” The challenge with pre-myeloma, Monoclonal
Continue readingRheumatologic Disease Inc. Risk of MGUS to Multiple Myeloma
“Patients with monoclonal gammopathy of undetermined significance (MGUS) have twice the risk of developing multiple myeloma (MM) if they have non-antibody (Ab)-mediated rheumatic diseases (RDs)…” Rheumatic
Continue readingMGUS, Myeloma AL Amyloidosis- Conventional, Non-Conventional
“Bortezomib with dexamethasone as first-line treatment for AL amyloidosis with renal involvement…in multiple myeloma or MGUS patients?” You’ve been diagnosed with multiple myeloma
Continue readingChemo for High Risk Smoldering Myeloma- Pain…
“…among the lenalidomide-treated patients, grade 3 or 4 hematologic and nonhematologic adverse events occurred in 36 patients (41%), with nonhematologic adverse events occurring in 25 patients
Continue reading